UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

~~SECTION~~Date 13of ORreport 15(dDate of earliest event reported): OFDecember ~~THE~~19, 2017

~~SECURITIES~~OMEGA ~~EXCHANGE~~PROTEIN ~~ACT~~CORPORATION OF(Exact ~~1934~~Name of Registrant as Specified in its Charter)

Date of report (Date of earliest event reported): November 27, 2017

Nevada	001-14003	76-0562134
(State or Other Jurisdiction of Incorporation or Organization)	(Commission File Number)	(I.R.S. Employer Identification No.)

2105 City West Boulevard Suite 500 Houston, Texas		77002
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (713) 623-0060

OMEGA PROTEIN CORPORATION

(Exact Name of Registrant as Specified in Charter)

Nevada		001-14003		76-0562134
(State or Other Jurisdiction of Incorporation or Organization)		(Commission File Number)		(I.R.S. Employer Identification No.)

2105 City West Boulevard Suite 500 Houston, Texas				77002
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s telephone number, including area code: (713) 623-0060

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☒☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 72.01. ~~Regulation~~Completion FDof ~~Disclosure~~Acquisition or Disposition of Assets.

On ~~November 27, 2017, Omega Protein Corporation, a Nevada Corporation (the “Company”), issued a press release announcing it has established a date of~~ December 19, 2017, ~~for~~pursuant ~~the special meeting of Company stockholders (the “Special Meeting”)~~ to ~~consider and vote upon a proposal to approve and adopt~~ the ~~previously announced~~ Agreement and Plan of Merger (the “Merger Agreement”), dated as of October 5, 2017, by and among Omega Protein Corporation (the “Company”), a Nevada corporation, Cooke Inc., a corporation duly incorporated under the laws of the Province of New Brunswick, Canada (“~~Cooke~~Parent”), and Alpha MergerSub, Inc., a Nevada corporation and ~~a direct~~ wholly owned subsidiary of ~~Cooke,~~Parent ~~and other related matters~~ (~~collectively, the~~ “~~Proposed~~Merger ~~Transaction~~Sub”)~~. In the press release~~, ~~the~~Parent ~~company~~completed ~~also~~its previously announced ~~that~~acquisition itof ~~has~~the ~~filed~~Company athrough ~~definitive~~the ~~proxy~~merger ~~statement~~of inMerger ~~connection~~Sub with and into the ~~Special~~Company ~~Meeting~~(the ~~and~~“Merger”), ~~expected~~with tothe ~~commence~~Company surviving the ~~mailing~~Merger ofas ~~definitive~~a ~~proxy~~wholly ~~materials~~owned onsubsidiary orof ~~about~~Parent ~~November~~(the ~~27,~~“Surviving ~~2017~~Corporation”). As ~~previously~~a ~~announced,~~result ~~only Company stockholders~~ of ~~record at~~ the ~~close of business on November 24~~Merger, ~~2017~~the ~~will~~Company beis ~~entitled~~wholly toowned ~~receive~~by ~~notice of and to vote at the Special Meeting~~Parent.

AAt ~~copy~~the effective time of the ~~press~~Merger ~~release~~on isDecember ~~attached~~19, as2017 ~~Exhibit~~(the 99“Effective Time”), (a) each outstanding share of common stock, par value $0.101 ~~hereto~~per ~~and~~share, ~~incorporated~~of the Company (“Common Stock”) (other than shares of Common Stock held by ~~reference~~the ~~herein~~Company or owned by Parent, Merger Sub or any direct or indirect wholly owned subsidiary of Parent or the Company) was automatically cancelled and converted into the right to receive $22. 00 in cash (the “Merger Consideration”), (b) each outstanding option to purchase shares of Common Stock (whether or not exercisable, each a “Stock Option”) issued pursuant to the Company 2006 Incentive Plan and the Company 2015 Long-Term Incentive Plan (together, the “Company Stock Plans”) was converted into the right to receive, less applicable withholding taxes, an amount in cash equal to the excess, if any, of the Merger Consideration payable in respect of a share of Common Stock over the applicable exercise price per share of Common Stock subject to the Stock Option (the “Option Consideration”) and (c) the restrictions applicable to each share of restricted Common Stock (“Restricted Stock”) immediately lapsed and each such share of Restricted Stock was converted into the right to receive the Merger Consideration, less applicable withholding taxes.

The foregoing description of the Merger Agreement and the Merger does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Merger Agreement, which was filed as Exhibit 2.1 to the Company’s Current Report on Form 8-K filed on October 6, 2017.

Item 3.01

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

The information included under Item 2.01 is incorporated into this Item 3.01 by reference.

Following the consummation of the Merger, the Company notified the New York Stock Exchange (the “NYSE”) that trading in the Common Stock should be suspended and the listing of the Common Stock on the NYSE should be removed. The Common Stock was suspended from trading on the NYSE prior to the opening of trading on December 20, 2017. The Company also requested that the NYSE file a Form 25 with the Securities and Exchange Commission (the “SEC”) to delist the Common Stock from the NYSE and to deregister the Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Furthermore, the Company intends to file with the SEC a Form 15 requesting that the reporting obligations of the Company under Sections 13(a) and 15(d) of the Exchange Act be suspended as soon as practicable.

Item 3.03

Material Modification to Rights of Security Holders.

The information included under Items 2.01, 3.01 and 5.01 is incorporated into this Item 3.03 by reference.

Pursuant to the Merger Agreement and subject to the terms and conditions thereof, at the Effective Time, (a) each outstanding share of Common Stock converted into the right to receive the Merger Consideration, (b) each outstanding Stock Option, converted into the right to receive the Option Consideration and (c) each share of restricted Common Stock converted into the right to receive the Merger Consideration, less applicable withholding taxes.

As of the Effective Time, Company stockholders immediately prior to the Effective Time ceased to have any rights as stockholders of the Company (other than the right to receive the Merger Consideration or as otherwise provided by the Merger Agreement or by law).

Item 5.01

Change in Control of Registrant

The information included under Item 2.01 and 3.03 is incorporated into this Item 5.01 by reference.

A change of control of the Company occurred on December 19, 2017, following the filing of the certificate of merger with the Secretary of State of the State of Nevada, at which time Merger Sub merged with and into the Company, with the Company continuing to exist as a Nevada corporation.

As a result of the Merger, the Company became a wholly owned subsidiary of Parent.

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements to Certain Officers.

At the Effective Time, and in accordance with the Merger Agreement, each member of the board of directors of the Company (the “Board”), other than Bret Scholtes, resigned from the Board and ceased to be a director of the Company. These directors are Dr. Celeste A. Clark, Michael N. Christodolou, Stephen C. Bryan, Gary R. Goodwin, David H. Clarke, David W. Wehlmann and David A. Owen. These resignations were required by the Merger Agreement and were not a result of any disagreements between the Company and the directors on any matter relating to the Company’s operations, policies or practices.

At the Effective Time, Glenn Cooke and Ross Butler were appointed as directors of the Company.

Glenn Cooke, age 52, founded Cooke Aquaculture in 1985 with his father Gifford and his brother Michael. He has been an officer and director of Parent and its affiliates since inception, currently serving as a Vice-President of Parent. Mr. Cooke has no family relationship to any director or executive officer of the Company. Mr. Cooke is an officer and indirect shareholder of Northeast Nutrition Inc., which carries on the business of manufacturing fish feed for use in the aquaculture industry. Northeast Nutrition Inc. is a customer of the Company and in 2017 to date has purchased approximately $1.586 million of fish meal and fish oil from the Company in the ordinary course of business at market rates.

Ross Butler, age 55, is currently the Chief Executive Officer of Wanchese Fish Company (“Wanchese”) and Cooke Seafood USA, based in Suffolk, VA. Wanchese is a third generation, 75-year-old seafood company that was acquired by the Cooke family in 2015. Prior to his appointment as CEO of Wanchese in 2015, Mr. Butler worked for Parent in several senior capacities including his most recent position as Senior Vice President responsible for their international harvesting and processing operations. Mr. Butler join Parent in 2002.

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

The information set forth under Item 2.01 is incorporated herein by reference.

At the Effective Time, the articles of incorporation of the Company, as in effect immediately prior to the Merger, were amended and restated in the form of the articles of incorporation filed as Exhibit 3.1 to this Current Report on Form 8-K which is incorporated herein by reference.

At the Effective Time, the bylaws of the Company, as in effect immediately prior to the Merger, were amended and restated in the form of the bylaws filed as Exhibit 3.2 to this Current Report on Form 8-K which are incorporated herein by reference.

Item 5.07.

Submission of Matters to a Vote of Security Holders.

On December 19, 2017, the Company convened its special meeting of stockholders (the “Special Meeting”) to vote on the proposals identified in the definitive proxy statement dated November 24, 2017, which was first mailed to Company stockholders on or about November 27, 2017.

As of the close of business on November 24, 2017, the record date for the Special Meeting, there were 22,478,928 shares of Common Stock outstanding and entitled to vote at the Special Meeting. A quorum of 18,082,241 shares of Common Stock was represented in person or by proxy at the Special Meeting. A summary of the voting results for the proposals presented, which are described in detail in the definitive proxy statement, is set forth below:

Proposal to adopt and approve the Merger Agreement (the “Merger Proposal”). The Merger Proposal received the affirmative vote of approximately 79.39% of the outstanding shares of Common Stock represented at the Special Meeting in person or by proxy.

Votes For		Votes Against		Votes Abstained		Broker Non-Votes
17,845,087		15,274		221,880		0

Advisory, non-binding proposal to approve compensation that will or may become payable to the Company’s named executive officers in connection with the Merger (the “Advisory, Non-Binding Compensation Proposal”). The Advisory, Non-Binding Compensation Proposal received the affirmative vote of approximately 31.75% of the outstanding shares of Common Stock represented at the Special Meeting in person or by proxy.

Votes For		Votes Against		Votes Abstained		Broker Non-Votes
7,138,016		10,699,696		244,526		0

Approval of the adjournment or postponement of the Special Meeting, if necessary or appropriate to solicit additional proxies if there are insufficient votes at the time of the Special Meeting to approve the Merger Proposal (the “Adjournment Proposal”). The Adjournment Proposal received the affirmative vote of approximately 75.04% of the outstanding shares of Common Stock represented at the Special Meeting in person or by proxy. However, as the Merger Proposal was approved, adjournment or postponement of the Special Meeting was unnecessary.

Votes For		Votes Against		Votes Abstained		Broker Non-Votes
16,868,360		981,106		232,770		0

No other business properly came before the Special Meeting.

Item 8.01.

Other Events.

ToOn ~~the~~December ~~extent~~19, ~~required~~2017, the ~~information~~Company ~~set~~issued ~~forth~~a inpress ~~Item~~release 7announcing the results of the stockholder vote at the Special Meeting.01 A copy of the press release is ~~incorporated~~attached ~~into~~as Exhibit 99.1 to this ~~Item~~Current Report on Form 8~~.01~~-K and is incorporated herein by reference.

Additional Information for Stockholders

This communication does not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities or a solicitation of any vote or approval. This communication relates to a proposed business combination between Cooke and the Company.

The Proposed Transaction will be submitted to the stockholders of the Company for their consideration. In connection with the Proposed Transaction, the Company has filed a definitive proxy statement with the Securities and Exchange Commission (“SEC”). In addition, the Company may also file other relevant documents with the SEC regarding the Proposed Transaction.

INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT(S) AND OTHER DOCUMENTS THAT HAVE BEEN OR MAY BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION.

Investors and security holders may obtain a free copy of the proxy statement(s) (when available) and other documents filed with the SEC by the Company at its website, www.omegaprotein.com, or at the SEC's website, www.sec.gov. The proxy statement(s) and other relevant documents may also be obtained for free from the Company by directing such request to Omega Protein Corporation, to the attention of the Corporate Secretary, 2105 City West Boulevard, Suite 500, Houston, Texas 77042, or by calling the Company’s proxy solicitor, Morrow Sodali LLC toll free at (800) 662-5200.

Participants in the Solicitation

The Company and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of the Company in connection with the Proposed Transaction. Information about the directors and executive officers of the Company is set forth in the Proxy Statement on Schedule 14A for the 2017 annual meeting of stockholders of the Company, which was filed with the SEC on April 28, 2017. This document can be obtained free of charge from the sources indicated above. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, is contained in the preliminary proxy statement and will be contained in the definitive proxy statement and other relevant materials to be filed with the SEC when they become available.

Cautionary Statement Regarding Forward-Looking Information

Forward-looking statements in this Form 8-K, future filings by the Company with the SEC, the Company’s press releases and oral statements by authorized officers of the Company are intended to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that all forward-looking statements involve risks and uncertainty. The Company believes that forward-looking statements made by it are based on reasonable expectations; however, no assurances can be given that actual results will not differ materially from those contained in such forward-looking statements. Forward-looking statements involve statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include the words “estimate,” “project,” “anticipate,” “expect,” “predict,” “assume,” “believe,” “could,” “would,” “hope,” “may” or similar expressions. In evaluating those statements, you should carefully consider the information above as well as the risks outlined in Item 1A. Risk Factors in the Company’s Form 10-K for the year ended December 31, 2016 and the Company’s Form 10-Qs for the quarters ended March 31, 2017, June 30, 2017 and September 30, 2017. The statements in this Form 8-K that are not historical statements are forward-looking statements within the meaning of the federal securities laws, including, among other things, statements regarding the expected timetable for completing the Proposed Transaction. These statements are subject to numerous risks and uncertainties, many of which are beyond the Company’s control, which could cause actual results to differ materially from the results expressed or implied by the statements. These risks and uncertainties include, but are not limited to: the failure to obtain the required votes of the Company’s stockholders; the timing to consummate the Proposed Transaction; the failure to satisfy the conditions to closing of the Proposed Transaction or the failure of the closing to occur; the risk that a regulatory or judicial approval (including United States Maritime Administration approval) that may be required to consummate the Proposed Transaction is not obtained or is obtained subject to conditions that are not anticipated; the diversion of management time on transaction-related issues; expectations regarding regulatory approval of the transaction; results of litigation, settlements and investigations; actions by third parties, including governmental agencies; global economic conditions; adverse industry conditions; adverse credit and equity market conditions; the loss of, or reduction in business with, key customers; legal proceedings; the ability to effectively identify and enter new markets; governmental regulation; the ability to retain management and other personnel; and other economic, business, or competitive factors.

Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements is contained from time to time in the Company’s SEC filings. The Company’s filings may be obtained by contacting the Company or the SEC or through the Company’s web site at www.omegaprotein.com or through the SEC’s Electronic Data Gathering and Analysis Retrieval System at http://www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statement.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits

99.1 Press release of Omega Protein Corporation dated November 27, 2017.

Exhibit Number		Description
3.1		Amended and Restated Articles of Incorporation of Omega Protein Corporation
3.2		Amended and Restated Bylaws of Omega Protein Corporation
99.1		Press Release, dated December 19, 2017, issued by Omega Protein Corporation.

SIGNATURES

Pursuant to the requirements of the ~~Securities~~ Exchange Act ~~of 1934~~, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	OMEGA PROTEIN CORPORATION		~~OMEGA PROTEIN CORPORATION~~
Date: November 27, 2017		By:	/s/ John D. Held
Date: December 22, 2017	By:	/s/ John D. Held
		John D. Held	~~John D. Held~~
		Executive Vice President, General Counsel and Secretary	~~Executive Vice President, General Counsel and Secretary~~

Exhibit Index

(d) Exhibits

Exhibit Number		Description
3.1		Amended and Restated Articles of Incorporation of Omega Protein Corporation
3.2		Amended and Restated Bylaws of Omega Protein Corporation
99.1		Press release of Omega Protein Corporation dated December 19, 2017.

~~99.1 Press release of Omega Protein Corporation dated November 27, 2017.~~5

Filing Compare · OMEGA PROTEIN CORP